VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Biopsy-proven LN Class III/IV±V (ISN/RPS 2003),    │ Biopsy-proven LN Class III/IV±V (ISN/RPS 2003),    │     100 │
│ with biopsy performed within 12 weeks of           │ with biopsy performed within 12 weeks of           │         │
│ randomization                                      │ randomization                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Positive anti-dsDNA                                │ Positive anti-dsDNA                                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Both 'incident' (i.e. new) patients and 'flare'    │ Both 'incident' (i.e. new) patients and 'flare'    │     100 │
│ patients can be included                           │ patients can be included                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Renal disease unrelated to SLE (e.g. diabetes      │ Renal disease unrelated to SLE (e.g. diabetes      │     100 │
│ mellitus, other glomerular or tubulointerstitial   │ mellitus, other glomerular or tubulointerstitial   │         │
│ disease, renovascular disease), or transplanted    │ disease, renovascular disease), or transplanted    │         │
│ kidney                                             │ kidney                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Renal biopsy showing cellular or fibrocellular     │ Renal biopsy showing cellular or fibrocellular     │     100 │
│ crescent in more than 25% of glomeruli             │ crescent in more than 25% of glomeruli             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ CNS or other severe organ manifestation of lupus   │ CNS or other severe organ manifestation of lupus   │     100 │
│ that necessitate aggressive immunosuppressive      │ that necessitate aggressive immunosuppressive      │         │
│ therapy on its own                                 │ therapy on its own                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Co-morbidities that require corticosteroid therapy │ Co-morbidities that require corticosteroid therapy │     100 │
│ (e.g. asthma, inflammatory bowel disease)          │ (e.g. asthma, inflammatory bowel disease)          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treatment with prednisolone (or prednisone, or     │ Treatment with prednisolone (or prednisone, or     │     100 │
│ equivalent) at \>20 mg/D for over 4 weeks within   │ equivalent) at >20 mg/D for over 4 weeks within    │         │
│ the past 3 months                                  │ the past 3 months                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known hypersensitivity or intolerability to        │ Known hypersensitivity or intolerability to        │     100 │
│ prednisolone (or prednisone, or equivalent), TAC,  │ prednisolone (or prednisone, or equivalent), TAC,  │         │
│ or MMF at a dose of 1.25 g or below per day        │ or MMF at a dose of 1.25 g or below per day        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who are already on treatment with TAC,    │ Subjects who are already on treatment with TAC,    │     100 │
│ cyclosporine or any other calcineurin inhibitor    │ cyclosporine or any other calcineurin inhibitor    │         │
│ for over 4 weeks within the past 12 months         │ for over 4 weeks within the past 12 months         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treatment with cyclophosphamide, leflunomide, or   │ Treatment with cyclophosphamide, leflunomide, or   │     100 │
│ methotrexate for over 2 weeks, or use of           │ methotrexate for over 2 weeks, or use of           │         │
│ biological agent(s) regardless of duration, within │ biological agent(s) regardless of duration, within │         │
│ the past 6 months (Note: prior use of              │ the past 6 months (Note: prior use of              │         │
│ azathioprine, mizoribine, intravenous              │ azathioprine, mizoribine, intravenous              │         │
│ immunoglobulins and anti-malarials is allowed)     │ immunoglobulins and anti-malarials is allowed)     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women who are pregnant or breastfeeding            │ Women who are pregnant or breastfeeding            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women with childbearing potential or their male    │ Women with childbearing potential or their male    │     100 │
│ partners, who refuse to use an effective birth     │ partners, who refuse to use an effective birth     │         │
│ control method                                     │ control method                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active LN with proteinuria (urine                  │ Active LN with proteinuria (urine                  │      99 │
│ protein/creatinine ratio \>1.0 or 24-hr urine      │ protein/creatinine ratio >1.0 or 24-hr urine       │         │
│ protein \>1.0 g at baseline), with or without      │ protein >1.0 g at baseline), with or without       │         │
│ hematuria                                          │ hematuria                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Estimated glomerular filtration rate (eGFR by      │ Estimated glomerular filtration rate (eGFR by      │      99 │
│ MDRD) ≤20 mL/min per 1.73 m2 or serum creatinine   │ MDRD) =20 mL/min per 1.73 m2 or serum creatinine   │         │
│ \>300 micromol/L (3.39 mg/dL) at screening         │ >300 micromol/L (3.39 mg/dL) at screening          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treatment with MMF at \>1.5 g/D for over 4 weeks   │ Treatment with MMF at >1.5 g/D for over 4 weeks    │      99 │
│ within the past 3 months                           │ within the past 3 months                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Uncontrolled hypertension with systolic BP \>160   │ Uncontrolled hypertension with systolic BP >160    │      99 │
│ mmHg or diastolic BP \>95 mmHg                     │ mmHg or diastolic BP >95 mmHg                      │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                           │   Score │
╞═══════════════════════════════════╪═════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Women who are pregnant or breastfeeding │      36 │
╘═══════════════════════════════════╧═════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 96.22222222222223
OverAll Ratio: 97.61111111111111
